Somewhat Favorable News Coverage Somewhat Unlikely to Affect IntelliPharmaCeutics Intl (IPCI) Share Price
Media coverage about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0822195777801 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of IntelliPharmaCeutics Intl (NASDAQ IPCI) traded down $0.03 during trading hours on Wednesday, hitting $0.75. 141,100 shares of the company’s stock were exchanged, compared to its average volume of 303,804. IntelliPharmaCeutics Intl has a 1 year low of $0.70 and a 1 year high of $3.12.
A number of research analysts have issued reports on IPCI shares. Zacks Investment Research upgraded shares of IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research report on Wednesday, December 13th. Mackie upgraded shares of IntelliPharmaCeutics Intl to a “hold” rating and increased their target price for the stock from $1.00 to $3.10 in a research report on Tuesday, September 26th. Finally, ValuEngine lowered shares of IntelliPharmaCeutics Intl from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $2.37.
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.